Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano, Orbassano

H�PITAL NORD - CHU MARSEILLE, Marseille

Complejo Hospitalario Universitario A Coruna, A Coru?a

Ico Girona Hospital Universitari de Girona Dr Josep Trueta, Girona

Spoknwrd Clinical Trials Inc., Easton

Irccs Istituto Clinico Humanitas, Rozzano

Hospital Universitario Ciudad de Jaen, Jaén

Hospital General Universitario Gregorio Maranon, Madrid

Hospital Universitario Ramon Y Cajal, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario de La Paz, Madrid

Hospital Universitario Hm Sanchinarro, Madrid

Hospital Regional Universitario de Malaga, Málaga

Chu de Toulouse Hopital Larrey Centre de Reference Des Maladies Rares de La Peau Service de Dermatol, Toulouse

Memorial Healthcare System, Pembroke Pines

Irccs Centro Di Riferimento Oncologico, Aviano

Miami Cancer Institute, Miami

Florida Cancer Specialists & Research Institute, Fort Myers

Lki Lungenfachklinik Immenhausen, Immenhausen

Tennessee Oncology, Nashville

University of Kentucky Hospital, Lexington

Hospital Universitario Virgen Macarena, Seville

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori, Meldola

Hospital Universitario Miguel Servet, Zaragoza

Azienda Ospedaliero Universitaria Pisana, Pisa

Lungenklinik Hemer, Hemer

University Hospital Mannheim, Mannheim

Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari, Bari

Valkyrie Clinical Trials, Los Angeles

Zentralklinik Bad Berka Gmbh, Bad Berka

Azienda Ospedaliera Di Perugia - Ospedale Santa Maria Della Misericordia, Perugia

Istituto Nazionale Tumori Regina Elena Irccs, Roma

Hospital General Universitario Vall D Hebron, Barcelona

Hospital Clinic de Barcelona, Barcelona

Hospital de La Santa Creu I Sant Pau, Barcelona

Ico Institut Catala D Oncologia, L'Hospitalet de Llobregat